Cargando…
An Exploratory Randomized Trial of SCO-792, an Enteropeptidase Inhibitor, in Patients With Type 2 Diabetes and Albuminuria
INTRODUCTION: Elevated plasma amino acid levels overload kidney function by increasing glomerular filtration rate (GFR). Inhibiting gut amino acid intake may have therapeutic benefits for patients with kidney dysfunction. For a prospective phase 2a trial, we carried out an exploratory evaluation of...
Autores principales: | Kagawa, Tomoya, Sugama, Jun, Nishizaki, Harunobu, Moritoh, Yusuke, Watanabe, Masanori |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831944/ https://www.ncbi.nlm.nih.gov/pubmed/36644351 http://dx.doi.org/10.1016/j.ekir.2022.10.006 |
Ejemplares similares
-
SCO‐792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice
por: Yashiro, Hiroaki, et al.
Publicado: (2019) -
Discovery and characterization of a small‐molecule enteropeptidase inhibitor, SCO‐792
por: Sasaki, Masako, et al.
Publicado: (2019) -
Enteropeptidase inhibitor SCO-792 effectively prevents kidney function decline and fibrosis in a rat model of chronic kidney disease
por: Katayama, Yuko, et al.
Publicado: (2020) -
Role of SCO-792, A Novel Enteropeptidase Inhibitor, In the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
por: Rashid, Mohammed Y, et al.
Publicado: (2021) -
SCO-267, a GPR40 Full Agonist, Stimulates Islet and Gut Hormone Secretion and Improves Glycemic Control in Humans
por: Nishizaki, Harunobu, et al.
Publicado: (2021)